The Dual Clinical Attention Layer

Nothing about a complex condition gets missed.

GDPR Article 9End-to-end encrypted for patient dataInformed-consent trail

For patients and families. For physicians: what Mēdota does inside the consultation. The model is built so the Krankenkasse funds it and the practice never pays.

scroll · keep reading
The New Way Forward — Intelligence That Gives the System Back Its Time.
I. Why this exists

Built by someone who lived through the gap twice.

“My son has a rare disease, and my father has Alzheimer’s. The situation is the same in both countries. Families are under great stress, and the doctors are overburdened. The risk of missing trials, of understanding the huge volume of research, and of being properly prepared for the doctors’ meetings is beyond challenging. Real human frustrations are unaddressed. So I built Mēdota for myself, for my son, for my father and for my mother. Then I saw that I could help millions, improve workflows, and perhaps reduce the number of patient visits to clinics. I went all in. The aim is that no family feels isolated or overwhelmed, and that clinics end up with the tools they believe do not exist.”Mattias Aybar, Founder
The cost moment

Every avoidable visit costs a family a day it does not have and a physician an hour that never comes back. Every European public payer sees the same pattern.

  • The family avoids the slow drain.
  • The physician gets the time back.
  • The Krankenkasse gets something it can measure, not a promise.
II. The gap
II. The gap, in numbers

Medical research is accelerating. Patients and doctors can’t keep up.

Life-changing discoveries are published every day. The people who need them most never hear about them.

5,000+
medical articles published every day.

Impossible to read, and not all of it can be trusted.
A 2026 screen flagged about 250,000 of 2.6 million cancer papers as possibly paper-mill-linked.

What matters is easy to miss. Relevance and quality are the point.

Source · scientific publishing volume analyses; QUT paper-mill screen (BMJ, 2026)

60M+
Europeans live with a rare disease, a cancer trajectory including life after cancer, an autoimmune or complex chronic condition, or Alzheimer's and neurodegenerative care. A floor, never a sum.
Source · European Commission · EUROCARE-6 · ECIS
4.7 years
average diagnostic odyssey for rare disease patients in Europe.
Source · EURORDIS Rare Barometer 2024
80–89%
of clinical trials miss their original enrolment timelines.
Source · Tufts CSDD Impact Reports
III. The system
III. The system, end to end

Set up once. Attention delivered daily.

The patient enters the conditions. The rest runs automatically, for both sides.

For the patient
I.

Set your conditions.

One condition or twenty. A personalised monitoring profile for each.

II.

We watch the whole picture, every night.

Eight streams. Symptoms, medications, documents, messages, appointments, research, trials, consent.

III.

AI scores relevance.

Only what matters reaches the dashboard. Relevance scoring filters the noise.

IV.

Arrive prepared.

In control of every appointment. AI-generated questions and exportable reports.

For the physician
I.

The visit is ready before the patient walks in.

Anamnesis prep, prior labs, current medications, open questions. One scrollable view.

II.

The documentation builds itself as you work.

The § 630e and § 630f BGB trail forms in the flow. Mēdota prepares and structures the documentation a billing decision rests on. Coding stays with the practice.

III.

Trials, research, labs, imaging, scanned every night.

Mēdota scans the literature and the patient’s record nightly. What matters for this patient reaches you. The rest, never.

IV.

The specialist still decides.

Mēdota surfaces; the physician decides. Less time on paperwork, less cost to the system, every clinical call still yours.

One dashboard. The whole of medical research, tuned to this patient.
IV. The platform

Every study. Every trial. Every signal. Filtered to what matters for this case.

Updated daily. End-to-end encrypted for patient data. On our reading the pilot version needs no CE certificate; we confirm that in writing before the funded German project uses it.

Two readers

Built for patients and physicians.

Plain language for patients. Clinical detail for physicians. German and English today; more languages to follow.

The watch

Continuous longitudinal monitoring.

PubMed, ClinicalTrials.gov, FDA, EMA, NIH grants, preprint servers. Thousands of sources, one dashboard.

The trial

Clinical trial visibility.

Every recruiting trial in your indication, matched by diagnosis, age, location, symptoms. Eligibility check stays with your doctor.

The questions

Questions for your doctor.

Discussion points specific to your case. Exportable as encrypted PDF.

The trail

Exportable, auditable reports.

Every alert exportable, with full source trail. Mēdota supports decisions, it does not make them.

§ Foundation

Built for EU health-data law, and for German ePA and Krankenkasse review.

Designed for operation with patient data: BSI C5-aligned, EU-sovereign-hosted, end-to-end encrypted, with a record of the physician’s duty to inform and of its documentation. In Germany those duties are § 630e BGB and § 630f BGB. Mēdota supports the physician in meeting them; the duty and the decision remain the physician’s. Patient data stays in the EU. Sponsors contact you only with your and your physician’s explicit consent. Cancel and your data is permanently deleted within thirty days.

V. For whom this is built

Built for every person living with a complex condition. And the physicians fighting alongside them.

More than 19 million people in Germany. More than 60 million across the EU. Both figures are floors, never sums. A rare disease, a cancer trajectory including life after cancer, an autoimmune or complex chronic condition, and Alzheimer’s and neurodegenerative care. Every one of them generating research no single clinician can track unaided.

Sources · BMG · RKI Zentrum für Krebsregisterdaten · Zi Versorgungsatlas 24/05, Akmatov et al. 2025 · Deutsche Alzheimer Gesellschaft (2023) · European Commission DG SANTE · EUROCARE-6, De Angelis et al., Lancet Oncol 2024 · Alzheimer Europe (2025) · Eurostat (1 January 2026)

For patients & families

Partner with your care team. Don’t chase it.

Understand what is happening. See every trial in your indication. Arrive at appointments with the right questions. Ready to partner with your care team, not chase it.

  • Plain-language summaries you can actually read.
  • Trial visibility based on your diagnosis. Eligibility stays with your doctor.
  • Exportable, shareable reports, revocable at any time.
For physicians

The time and the legal cover you deserve.

Pre-ranked, patient-linked feed. Mēdota surfaces; the physician decides.

Detects when a new treatment crosses from trial into the medical standard. Surfaces comparative evidence on alternatives. Support for § 630e BGB Aufklärungspflicht. Visit prep and consultation drafts build the § 630f BGB documentation trail.

  • Priority alerts ranked by clinical significance and patient match.
  • Patient-ready summaries delivered before the appointment.
  • Full source trail. Every claim is traceable.
VI. What comes next